BACKGROUND/ OBJECTIVE: Despite multiple attempts, no surrogate biomarker of Parkinson disease (PD) has been definitively identified. Alternatively, identifying a non-invasive biomarker is crucial to understanding the natural history, severity, and progression of PD and to guide future therapeutic trials. Recent work highlighted alpha synuclein-containing extracellular vesicles and Poly (ADP-ribose) polymerase (PARP-1) activity as drivers of PD pathogenesis and putative PD biomarkers. This exploratory study evaluated the role of alpha-synuclein-positive extracellular vesicles and PARP-1 activity in the plasma of PD patients as non-invasive markers of the disease's severity and progression. METHODS: We collected plasma of 57 PD patients (discovery cohort 20, replication cohort 37) and compared it with 20 unaffected individuals, 20 individuals with clinically diagnosed Alzheimer's disease, and 20 individuals with dementia with Lewy bodies. We analyzed alpha-synuclein-positive extracellular vesicles from platelet-free plasma by nanoscale flow cytometry and blood concentrations of poly ADP-ribose using sandwich ELISA kits. RESULTS: Median concentration of α-synuclein extracellular vesicles was significantly higher in PD patients compared to the other groups (Kruskal-Wallis, p < .0001). In the discovery cohort, patients with higher α-synuclein extracellular vesicles had a higher Unified Parkinson Disease Rating Scale score (UPDRS III median = 22 vs. 5, p = 0.045). Seven out of 20 patients (35%) showed detectable PAR levels, with positive patients showing significantly higher levels of α-synuclein extracellular vesicles. In the replication cohort, we did not observe a significant difference in the PAR-positive cases in relationship with UPDRS III. CONCLUSIONS: Non-invasive determination of α-synuclein-positive extracellular vesicles may provide a potential non-invasive marker of PD disease severity, and longitudinal studies are needed to evaluate the role of α-synuclein-positive extracellular vesicles as a marker of disease progression.
BACKGROUND/ OBJECTIVE: Despite multiple attempts, no surrogate biomarker of Parkinson disease (PD) has been definitively identified. Alternatively, identifying a non-invasive biomarker is crucial to understanding the natural history, severity, and progression of PD and to guide future therapeutic trials. Recent work highlighted alpha synuclein-containing extracellular vesicles and Poly (ADP-ribose) polymerase (PARP-1) activity as drivers of PD pathogenesis and putative PD biomarkers. This exploratory study evaluated the role of alpha-synuclein-positive extracellular vesicles and PARP-1 activity in the plasma of PD patients as non-invasive markers of the disease's severity and progression. METHODS: We collected plasma of 57 PD patients (discovery cohort 20, replication cohort 37) and compared it with 20 unaffected individuals, 20 individuals with clinically diagnosed Alzheimer's disease, and 20 individuals with dementia with Lewy bodies. We analyzed alpha-synuclein-positive extracellular vesicles from platelet-free plasma by nanoscale flow cytometry and blood concentrations of poly ADP-ribose using sandwich ELISA kits. RESULTS: Median concentration of α-synuclein extracellular vesicles was significantly higher in PD patients compared to the other groups (Kruskal-Wallis, p < .0001). In the discovery cohort, patients with higher α-synuclein extracellular vesicles had a higher Unified Parkinson Disease Rating Scale score (UPDRS III median = 22 vs. 5, p = 0.045). Seven out of 20 patients (35%) showed detectable PAR levels, with positive patients showing significantly higher levels of α-synuclein extracellular vesicles. In the replication cohort, we did not observe a significant difference in the PAR-positive cases in relationship with UPDRS III. CONCLUSIONS: Non-invasive determination of α-synuclein-positive extracellular vesicles may provide a potential non-invasive marker of PD disease severity, and longitudinal studies are needed to evaluate the role of α-synuclein-positive extracellular vesicles as a marker of disease progression.
Authors: Shaida A Andrabi; No Soo Kim; Seong-Woon Yu; Hongmin Wang; David W Koh; Masayuki Sasaki; Judith A Klaus; Takashi Otsuka; Zhizheng Zhang; Raymond C Koehler; Patricia D Hurn; Guy G Poirier; Valina L Dawson; Ted M Dawson Journal: Proc Natl Acad Sci U S A Date: 2006-11-20 Impact factor: 11.205
Authors: Alberto J Espay; Joaquin A Vizcarra; Luca Marsili; Anthony E Lang; David K Simon; Aristide Merola; Keith A Josephs; Alfonso Fasano; Francesca Morgante; Rodolfo Savica; J Timothy Greenamyre; Franca Cambi; Tritia R Yamasaki; Caroline M Tanner; Ziv Gan-Or; Irene Litvan; Ignacio F Mata; Cyrus P Zabetian; Patrik Brundin; Hubert H Fernandez; David G Standaert; Marcelo A Kauffman; Michael A Schwarzschild; S Pablo Sardi; Todd Sherer; George Perry; James B Leverenz Journal: Neurology Date: 2019-02-12 Impact factor: 9.910
Authors: Juan F Reyes; Tomas T Olsson; Jennifer T Lamberts; Michael J Devine; Tilo Kunath; Patrik Brundin Journal: Neurobiol Dis Date: 2014-07-16 Impact factor: 5.996
Authors: Cheng Jiang; Franziska Hopfner; Antigoni Katsikoudi; Robert Hein; Candan Catli; Samuel Evetts; Yongzhi Huang; Hong Wang; John W Ryder; Gregor Kuhlenbaeumer; Guenther Deuschl; Alessandro Padovani; Daniela Berg; Barbara Borroni; Michele T Hu; Jason J Davis; George K Tofaris Journal: J Neurol Neurosurg Psychiatry Date: 2020-04-09 Impact factor: 10.154
Authors: Gabriel Gustafsson; Camilla Lööv; Emma Persson; Diana F Lázaro; Shuko Takeda; Joakim Bergström; Anna Erlandsson; Dag Sehlin; Leonora Balaj; Bence György; Martin Hallbeck; Tiago F Outeiro; Xandra O Breakefield; Bradley T Hyman; Martin Ingelsson Journal: Cell Mol Neurobiol Date: 2018-10-04 Impact factor: 5.046
Authors: Jessica Valencia; Marta Ferreira; J Francisco Merino-Torres; Antonio Marcilla; Jose M Soriano Journal: Int J Mol Sci Date: 2022-09-29 Impact factor: 6.208